TARA: Protara Therapeutics, Inc. Stock

by  •  • Comments Off on TARA: Protara Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 47.15
Enterprise Value ($M) -5.08
Book Value ($M) 58.41
Book Value / Share 2.84
Price / Book 0.81
NCAV ($M) 48.19
NCAV / Share 2.34
Price / NCAV 0.98

Profitability (mra)
Return on Invested Capital (ROIC) -0.67
Return on Assets (ROA) -0.45
Return on Equity (ROE) -0.50

Liquidity (mrq)
Quick Ratio 10.53
Current Ratio 10.53

Balance Sheet (mrq) ($M)
Current Assets 57.91
Assets 68.13
Liabilities 9.73
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -43.61
Net Income -40.42
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -37.56
Cash from Investing 53.11
Cash from Financing -0.09

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-25 13G Ra Capital Management, L.p. 9.99 23.46
04-22 13G Citadel Advisors Llc 5.70
04-09 13G CVI Investments, Inc. 5.30
02-14 13G/A Orbimed Advisors Llc 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PUR
2024-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT
2023-08-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURS

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-07-26 11,974 98,329 12.18
2024-07-25 38,453 88,449 43.47
2024-07-24 1,700 13,616 12.49
2024-07-23 5,811 34,560 16.81
2024-07-22 38,526 84,944 45.35

(click for more detail)

Similar Companies
SPRY – ARS Pharmaceuticals, Inc. STRO – Sutro Biopharma, Inc.
SUPN – Supernus Pharmaceuticals, Inc. TBPH – Theravance Biopharma, Inc.
TCRX – TScan Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io